Home > Dermatology > SPIN 2019 > Novel Considerations > Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?

Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?

Presented By
Prof. Kristian Reich, Georg-August-University Göttingen, Germany
Conference
SPIN 2019
Trial
ECLIPSE
Guselkumab demonstrated superior long-term responses compared with secukinumab in the treatment of moderate-to-severe plaque psoriasis in the first head-to-head trial (the ECLIPSE study) comparing an IL-23 inhibitor (guselkumab) to an IL-17 inhibitor (secukinumab); but there may be limitations to these data and more research is needed. Prof. Kristian Reich (Georg-August-University Göttingen, Germany) reminded us that there are two main novel classes of drugs in psoriasis, the IL-17 and IL-23 inhibitors, and it will be interesting to discover what their similarities and differences might be in clinical outcomes [1]. The role that the cytokines play in the pathological cascade of psoriasis is very different; for example, while anti-IL-23 drugs can allow you to go to longer injection intervals, you have a very rapid onset of ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on